Generate Biomedicines (GENB) EBITDA Yield: History & Chart

Generate Biomedicines, Inc.(GENB)

Biotechnology · Somerville, MA

$13.80-0.11 (-0.79%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Generate Biomedicines, Inc.

Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.

Somerville, MA

312 employees

generatebiomedicines.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael T. Nally

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Generate Biomedicines, Inc. (GENB)	$1.77B	N/A	N/A	N/A	N/A
Surgery Partners, Inc. (SGRY)vs ›	$1.75B	10.40%	9.93%	8.18%	7.57%
Novocure Ltd (NVCR)vs ›	$1.74B	N/A	0.15%	0.15%	0.15%
Absci Corporation (ABSI)vs ›	$1.74B	N/A	N/A	N/A	N/A
Alignment Healthcare, Inc. (ALHC)vs ›	$1.74B	6.30%	1.74%	1.49%	1.49%
Xencor, Inc. (XNCR)vs ›	$1.81B	N/A	4.10%	3.58%	2.82%
LeMaitre Vascular, Inc. (LMAT)vs ›	$1.81B	4.61%	3.36%	3.12%	3.44%
Intellia Therapeutics, Inc. (NTLA)vs ›	$1.73B	N/A	N/A	N/A	N/A
Xeris Biopharma Holdings, Inc. (XERS)vs ›	$1.74B	2.57%	2.78%	2.43%	2.43%
Azenta, Inc. (AZTA)vs ›	$1.81B	2.04%	4.45%	3.20%	2.40%

NAME

MARKET CAP

EBITDA YIELD

TTM

Generate Biomedicines, Inc. (GENB)

$1.77B

N/A

Surgery Partners, Inc. (SGRY)vs ›

$1.75B

10.40%

9.93%

8.18%

7.57%

Novocure Ltd (NVCR)vs ›

$1.74B

N/A

0.15%

Absci Corporation (ABSI)vs ›

$1.74B

N/A

Alignment Healthcare, Inc. (ALHC)vs ›

$1.74B

6.30%

1.74%

1.49%

Xencor, Inc. (XNCR)vs ›

$1.81B

N/A

4.10%

3.58%

2.82%

LeMaitre Vascular, Inc. (LMAT)vs ›

$1.81B

4.61%

3.36%

3.12%

3.44%

Intellia Therapeutics, Inc. (NTLA)vs ›

$1.73B

N/A

Xeris Biopharma Holdings, Inc. (XERS)vs ›

$1.74B

2.57%

2.78%

2.43%

Azenta, Inc. (AZTA)vs ›

$1.81B

2.04%

4.45%

3.20%

2.40%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

GENB EBITDA Yield Metrics

GENB Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics